Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
about
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen speciesMethylation mattersHigh-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistanceA novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinomaDoxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapyDemethylating Agents in the Treatment of CancerMolecular mechanism of chemoresistance by astrocyte elevated gene-1.DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.Molecular pathways: regulation and therapeutic implications of multidrug resistancePrecipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.Drug resistance in cancer: an overview.Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells.Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT.Troglitazone reverses the multiple drug resistance phenotype in cancer cells.Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistancePromoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.Uncovering the DNA methylome in chronic lymphocytic leukemia.Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cellsGlobal DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine.Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma.
P2860
Q28349324-649BF1CA-DD9B-4636-8D7C-46352D55ABCAQ28364163-12256C29-663C-4428-9442-4502B2D1F14FQ28474284-3D26FC9A-1B4A-44A3-8DF8-5AF0CFBC2244Q28479007-04802E72-A1F4-4E4F-ADD0-06BC1B0C5180Q30886810-CB67672F-4FB5-4DEB-95BD-B7E8D8F0BD98Q33357010-5F336DA0-DC37-4054-9D93-68362C712E9EQ33678040-B010CD09-1F39-4266-9C0D-5B062FFCA9B3Q33793969-3318D5D4-10DA-480E-9CCE-2111ED1120CAQ33816178-1B1131F3-A497-44CF-89E6-3BEA4A1CF518Q34255292-3EC8FE82-06F5-4A74-BD82-B5E2660567D5Q34324051-1FB8ED0D-B277-40ED-ADD3-09761A5F4BDCQ34437369-A7940868-00B4-494A-B163-08733A9193F3Q34928974-2BC7314D-BFBD-4225-ACA1-A8E24981DDFBQ35176904-47E75DBD-F047-4A06-B11B-0916D9088ACAQ35327711-488819AF-DDA5-48CD-95C9-A448431BDFB0Q35984641-430031CF-5C87-4AAF-A354-5E79B7D44EF0Q37003304-DB3AA26A-D02A-4F5E-B3EE-FEA2A79308FCQ37403238-FC7856EC-06C5-4BAF-9B9A-B9D9937F617FQ37478653-E605611B-6C1C-4CF2-8C89-3208FF0911D5Q37687390-D2F7EED1-732A-4CB6-8A99-6222732785F4Q38074267-6BE0CE80-87EC-425C-B3A8-C66DE27AAAE8Q39658359-22F36FDA-7C54-41F4-A6F5-5A122B111E1FQ40099844-EA56E9FD-1572-4C92-A249-EEC9D5C8BE98Q40381466-78CBE0A0-8599-4C57-BF1D-D167B6D6480EQ43150766-B7C40953-2FCB-4CE8-A2B2-706BA1F13548Q45641138-4D43FD00-E047-465C-B3C5-BA1490641A64
P2860
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Altered methylation of the hum ...... acquired multidrug resistance.
@ast
Altered methylation of the hum ...... acquired multidrug resistance.
@en
Altered methylation of the hum ...... acquired multidrug resistance.
@nl
type
label
Altered methylation of the hum ...... acquired multidrug resistance.
@ast
Altered methylation of the hum ...... acquired multidrug resistance.
@en
Altered methylation of the hum ...... acquired multidrug resistance.
@nl
prefLabel
Altered methylation of the hum ...... acquired multidrug resistance.
@ast
Altered methylation of the hum ...... acquired multidrug resistance.
@en
Altered methylation of the hum ...... acquired multidrug resistance.
@nl
P2093
P1476
Altered methylation of the hum ...... acquired multidrug resistance
@en
P2093
J D Parkin
J R Zalcberg
P Kantharidis
P304
P407
P577
1997-11-01T00:00:00Z